Neoadjuvant Nivolumab plus Chemotherapy Increased Pathological Complete Response Rate in CheckMate-816 Lung Cancer Trial
PHILADELPHIA – Adding nivolumab (Opdivo) to chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)...